title: Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak®on CD25+cells.
abstract: Ontak®, a conjugate between IL-2 and a diphtheria toxin fragment, was recently investigated in cancer clinical trials aiming to kill CD25+regulatory T cells (Tregs). We found that the activity of Ontak®was more complex on Tregsand conventional T cells (Tconvs) than anticipated, including a novel strong influence on dendritic cells (DCs).
authors: Institute of Virology and Immunobiology; University of Wuerzburg; Wuerzburg, Germany.
authors: Manfred B
authors: MB
authors: Lutz
authors: Department of Dermatology; University Hospital Erlangen; Erlangen, Germany.
authors: Andreas S
authors: AS
authors: Baur
authors: Department of Dermatology; University Hospital Erlangen; Erlangen, Germany.
authors: Beatrice
authors: B
authors: Schuler-Thurner
authors: Department of Dermatology; University Hospital Erlangen; Erlangen, Germany.
authors: Gerold
authors: G
authors: Schuler
keywords: Ontak; T cells; dendritic cells; interleukin-2 receptor; regulatory T cells